ClariVest Asset Management’s Achillion Pharmaceuticals ACHN Stock Holding History

ClariVest Asset Management’s Portfolio ACHN Stock Details ACHN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-141,671	Closed	-$409K	–	796
2017 Q4	$409K	Sell	141,671 -9,268	-6%	-$33.7K	0.01%	513
2017 Q3	$678K	Hold	150,939	–	–	0.02%	367
2017 Q2	$693K	Sell	150,939 -101	-0.1%	-$406	0.02%	365
2017 Q1	$636K	Hold	151,040	–	–	0.02%	374
2016 Q4	$624K	Buy	+151,040	New	+$803K	0.02%	384

Other funds holding ACHN

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

ClariVest Asset Management's ACHN Position: Q1 2018 in Review

ClariVest Asset Management sold out of Achillion Pharmaceuticals (ACHN) in Q1 2018, closing a stake of 141,671 shares — an estimated $409K sold.

ClariVest Asset Management first reported a position in ACHN in Q4 2016 and held it in 5 quarters. The position peaked at $693K in Q2 2017. 127 funds tracked by Wall St. Rank hold ACHN as of Q1 2018.

ClariVest Asset Management reported no remaining Achillion Pharmaceuticals position as of Q1 2018 after selling out during the quarter.
ClariVest Asset Management sold 141,671 Achillion Pharmaceuticals shares in Q1 2018, an estimated $409K.
ClariVest Asset Management first reported a position in Achillion Pharmaceuticals in Q4 2016 and held it in 5 quarters.
ClariVest Asset Management's Achillion Pharmaceuticals position peaked at $693K in Q2 2017.
127 funds tracked by Wall St. Rank held Achillion Pharmaceuticals as of Q1 2018.

Based on ClariVest Asset Management's 13F filing for Q1 2018, filed 8 May 2018.